101
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

A forodesine-based regimen as a therapeutic option for PTCL-NOS with Central nervous system involvement

ORCID Icon, , ORCID Icon, , , , , & show all
Pages 1013-1015 | Received 28 May 2021, Accepted 07 Nov 2021, Published online: 02 Dec 2021
 

Acknowledgments

We appreciate all of the staff at the Osaka University Hospital who were involved in the medical care of the patient.

Ethical approval

The study design was approved by the ethics committee of our institute and informed consent was obtained from the patient.

Disclosure statement

H. Shibayama has received honoraria from Takeda, and Celgene. K. Matsumoto has received 100 mg bulk powder of forodesine and research fund from Mundipharma. Scholarship endowment from Mundipharma is provided for the Department of Hematology and Oncology, Osaka University Graduate School of Medicine.

Additional information

Funding

This study is supported by Celgene, Mundipharma International, and Takeda Pharmaceutical Company.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.